Research Reports Coverage on Medical Instruments & Supplies Stocks -- DENTSPLY Intl., Endologix, OraSure Technologies, and TransEnterix

Sep 02, 2016, 08:05 ET from Chelmsford Park SA

NEW YORK, September 2, 2016 /PRNewswire/ --

Given the solid demand for healthcare-related products and services, the Medical Instruments and Supplies industry remains a strong but highly competitive space. Today, has initiated research reports on four equities to look for growth opportunities ahead: DENTSPLY International Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), OraSure Technologies Inc. (NASDAQ: OSUR), and TransEnterix Inc. (NYSE MKT: TRXC). These stocks research reports can be downloaded now by simply registering for free at:


On Thursday, shares in York, Pennsylvania headquartered DENTSPLY International Inc. recorded a trading volume of 992,172 shares. The stock ended the day at $61.65, climbing 0.31%. The Company's shares have gained 1.57% on an YTD basis. The stock is trading above its 200-day moving average by 1.55%. Furthermore, shares of DENTSPLY International, which designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the US and internationally, have a Relative Strength Index (RSI) of 51.30.

On August 5th, 2016, DENTSPLY International reported net sales of $1.02 billion increased 46.4%, compared to $698.0 million in Q2 2015. Sales of the combined businesses grew 3.4% at constant currency exchange rates during the three month period ending June 30th, 2016. Net income attributable to DENTSPLY for Q2 2016 was $105.4 million, or $0.44 per diluted share, compared to $44.1 million, or $0.31 per diluted share, in Q2 2015.

On August 08th, 2016, research firm Barrington Research downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Your complete research report on XRAY can be retrieved for free at:


Irvine, California headquartered Endologix Inc.'s stock finished yesterday's session 0.49% higher at $12.22 and with a total volume of 654,900 shares traded. The Company's shares have gained 1.92% in the last one month and 23.43% on an YTD basis. The stock is trading above its 200-day moving average by 15.90%. Furthermore, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 50.18.

On August 03rd, 2016, research firm RBC Capital Markets downgraded the Company's stock rating from 'Outperform' to 'Sector Perform'. The research firm also revised downwards its previous target price from $17 to $12.

On August 17th, 2016, Endologix announced that the first two patients with abdominal aortic aneurysms have been treated with the Ovation Alto™ Abdominal Stent Graft System. Ovation Alto is the newest device in the Ovation® platform of abdominal stent graft systems, which has excellent clinical results reported from the Ovation global pivotal trial and a 501-patient European Post-Market Registry. Ovation Alto expands EVAR to include the treatment of patients with complex AAAs, specifically patients with very short or otherwise challenging aortic neck anatomy. ELGX free report is just a click away at:

OraSure Technologies  

At the closing bell on Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. saw a slight decline of 0.12%, ending the day at $8.56. The stock recorded a trading volume of 720,019 shares. The Company's shares have advanced 25.70% in the last one month, 9.53% in the previous three months, and 32.92% since the start of this year. The stock is trading 24.57% above its 50-day moving average and 27.38% above its 200-day moving average. Moreover, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have an RSI of 82.72.

On August 23rd, 2016, OraSure Technologies announced that it has been awarded a contract for up to $16.6 million in total funding from the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority to advance the Company's rapid Zika tests. Sign up for your complimentary research report on OSUR at:


Morrisville, North Carolina headquartered TransEnterix Inc.'s stock ended the day flat at $1.37 and with a total volume of 363,820 shares traded. Shares of the Company, which focuses on the development and commercialization of surgical robotic systems, are trading 2.15% above their 50-day moving average. The stock has an RSI of 48.92.

On August 5th, 2016, TransEnterix announced that for the three months ended June 30th, 2016, on a consolidated GAAP basis, net loss was $80.1 million and net loss per share was $0.70. Excluding the restructuring and goodwill impairment charges, adjusted net loss was $12.7 million, or $0.11 per share. The Company had cash and cash equivalents of approximately $61.0 million as of July 31st, 2016. TransEnterix expects its existing cash and cash equivalents to fund operations through Q3 2017. Register for free on and download the latest research report on TRXC at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA